On July 22, Akeso rose 4.39% in regular trading, trading at HK$100.8/share, with turnover of HK$258 million.

On the news front, Akeso recently announced that its novel Trop2/Nectin-4 bispecific antibody-drug conjugate (AK146D1) in combination with ivonescimab (PD-1/VEGF bispecific antibody) has completed first patient dosing in a Phase II clinical study for advanced non-small cell lung cancer. The study aims to evaluate safety and preliminary efficacy, particularly in the first-line NSCLC setting. This milestone marks the companys IO2.0+ADC2.0 dual-platform strategy entering a critical advancement stage, with multiple next-generation ADC candidates now in Phase II development.

The broader biotechnology sector also provided support, with Remegen up 4.46%, 3SBio up 4.20%, Innovent Bio up 2.12%, and BeiGene up 1.97%. Multiple brokerages have recently maintained buy ratings on Akeso, with CITIC Construction noting the companys globally competitive Tetrabody bispecific antibody technology platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)